Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.780
+0.040 (2.30%)
At close: Nov 1, 2024, 4:00 PM
1.740
-0.040 (-2.25%)
After-hours: Nov 1, 2024, 6:59 PM EDT
Heron Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 136.36 | 127.04 | 107.67 | 86.35 | 88.64 | 145.97 | Upgrade
|
Revenue Growth (YoY) | 15.60% | 17.99% | 24.70% | -2.59% | -39.28% | 88.41% | Upgrade
|
Cost of Revenue | 95.78 | 117 | 158.18 | 175.64 | 209.52 | 229 | Upgrade
|
Gross Profit | 40.59 | 10.04 | -50.51 | -89.3 | -120.88 | -83.03 | Upgrade
|
Selling, General & Admin | 79.21 | 103.06 | 118.75 | 127.13 | 101.68 | 127.66 | Upgrade
|
Operating Expenses | 69.38 | 103.06 | 118.75 | 127.13 | 101.68 | 127.66 | Upgrade
|
Operating Income | -28.79 | -93.02 | -169.26 | -216.43 | -222.56 | -210.69 | Upgrade
|
Interest Expense | -5.57 | -3.87 | -2.47 | -2.41 | -1.9 | -1.47 | Upgrade
|
Interest & Investment Income | 3.36 | 3.36 | 1.64 | 0.43 | 3.63 | 7.26 | Upgrade
|
Other Non Operating Income (Expenses) | 3.28 | 1.18 | -6.32 | -0.4 | - | 0.26 | Upgrade
|
EBT Excluding Unusual Items | -27.72 | -92.34 | -176.42 | -218.81 | -220.83 | -204.65 | Upgrade
|
Merger & Restructuring Charges | -4.2 | -4.2 | -5.4 | -1.4 | -5.6 | - | Upgrade
|
Gain (Loss) on Sale of Investments | -0 | -0 | - | - | - | 0.01 | Upgrade
|
Asset Writedown | -0.31 | -0.62 | -0.21 | -0.48 | -0.85 | -0.11 | Upgrade
|
Other Unusual Items | -13.4 | -13.4 | - | - | - | - | Upgrade
|
Pretax Income | -48.13 | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 | Upgrade
|
Net Income | -48.13 | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 | Upgrade
|
Net Income to Common | -48.13 | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 | Upgrade
|
Shares Outstanding (Basic) | 154 | 138 | 109 | 98 | 91 | 82 | Upgrade
|
Shares Outstanding (Diluted) | 154 | 138 | 109 | 98 | 91 | 82 | Upgrade
|
Shares Change (YoY) | 31.37% | 26.87% | 10.57% | 8.48% | 11.00% | 11.73% | Upgrade
|
EPS (Basic) | -0.31 | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 | Upgrade
|
EPS (Diluted) | -0.31 | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 | Upgrade
|
Free Cash Flow | -22.52 | -60.33 | -148.74 | -206.38 | -191.63 | -131.73 | Upgrade
|
Free Cash Flow Per Share | -0.15 | -0.44 | -1.37 | -2.10 | -2.11 | -1.61 | Upgrade
|
Gross Margin | 29.76% | 7.90% | -46.91% | -103.42% | -136.38% | -56.88% | Upgrade
|
Operating Margin | -21.11% | -73.21% | -157.20% | -250.65% | -251.09% | -144.34% | Upgrade
|
Profit Margin | -35.29% | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | Upgrade
|
Free Cash Flow Margin | -16.52% | -47.49% | -138.14% | -239.01% | -216.20% | -90.25% | Upgrade
|
EBITDA | -26.02 | -90.12 | -166.37 | -213.41 | -219.72 | -208.65 | Upgrade
|
EBITDA Margin | -19.08% | -70.93% | -154.51% | -247.15% | -247.88% | -142.94% | Upgrade
|
D&A For EBITDA | 2.77 | 2.9 | 2.89 | 3.02 | 2.85 | 2.04 | Upgrade
|
EBIT | -28.79 | -93.02 | -169.26 | -216.43 | -222.56 | -210.69 | Upgrade
|
EBIT Margin | -21.11% | -73.21% | -157.20% | -250.65% | -251.09% | -144.34% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.